Perimenopause brings significant hormonal shifts that can affect many aspects of health, including liver function. Non-alcoholic fatty liver disease (NAFLD) is increasingly common in midlife women, and research suggests the menopausal transition may heighten susceptibility to liver fat accumulation. Whilst perimenopause does not directly cause fatty liver, declining oestrogen levels can trigger metabolic changes—such as insulin resistance, altered lipid profiles, and increased abdominal fat—that raise NAFLD risk. Understanding this connection is vital for women navigating perimenopause, as early recognition and lifestyle interventions can protect liver health and prevent disease progression during this critical life stage.

Understanding Fatty Liver and Perimenopause

Non-alcoholic fatty liver disease (NAFLD) is a condition characterised by excessive fat accumulation in the liver in people who consume little to no alcohol. It is a diagnosis of exclusion, made after ruling out significant alcohol intake (typically defined as >14 units per week for women in the UK), viral hepatitis, autoimmune liver disease, and other causes of chronic liver disease. NAFLD represents a spectrum of liver conditions, ranging from simple steatosis (fat accumulation) to non-alcoholic steatohepatitis (NASH), which involves inflammation and potential liver damage. You may also see the term metabolic dysfunction-associated steatotic liver disease (MASLD) in newer guidance, though NHS and NICE resources commonly use NAFLD.

NAFLD has become increasingly prevalent in the UK, affecting up to one in three adults, and is closely associated with metabolic conditions such as obesity, type 2 diabetes, and cardiovascular disease.

Perimenopause refers to the transitional period leading up to menopause, typically beginning in a woman's 40s but sometimes earlier. During this phase, which can last several years, the ovaries gradually produce less oestrogen and progesterone, leading to irregular menstrual cycles and various physical and psychological symptoms. Common manifestations include hot flushes, night sweats, mood changes, sleep disturbances, and alterations in body composition.

The relationship between perimenopause and liver health has garnered increasing attention in recent years. Research suggests that the hormonal fluctuations characteristic of this life stage may influence metabolic processes that affect the liver. Women often experience changes in fat distribution during perimenopause, with a tendency towards increased central (abdominal) adiposity, which is a known risk factor for NAFLD.

Understanding the potential connection between these two conditions is important for women's health, as both perimenopause and fatty liver disease typically occur during midlife. Recognising how hormonal changes may impact liver health can help women and healthcare professionals implement appropriate preventive strategies and monitoring during this transitional period.

Can Perimenopause Cause Fatty Liver Disease?

Whilst perimenopause itself does not directly cause fatty liver disease, emerging evidence suggests that the hormonal changes during this transition may increase a woman's susceptibility to developing NAFLD. The relationship is complex and multifactorial rather than a simple cause-and-effect mechanism.

Several observational studies have demonstrated that the prevalence of NAFLD increases in women after menopause compared to premenopausal women of similar age. Research published in hepatology journals indicates that postmenopausal women may have a higher risk of fatty liver disease than premenopausal women, even after adjusting for age and body mass index (BMI). This suggests that the decline in oestrogen levels may play a contributory role, though there is no official link establishing perimenopause as a direct cause.

The timing of NAFLD development often coincides with the perimenopausal transition, which typically occurs between ages 45 and 55. During this period, women experience significant metabolic changes that can predispose them to liver fat accumulation. These include alterations in insulin sensitivity, changes in lipid metabolism, redistribution of body fat towards the abdomen, and modifications in energy expenditure.

It is important to emphasise that multiple factors contribute to fatty liver disease development. Whilst hormonal changes during perimenopause may increase vulnerability, other elements such as diet, physical activity levels, genetic predisposition, and pre-existing metabolic conditions play equally important roles. Women with risk factors such as obesity, insulin resistance, or metabolic syndrome are more likely to develop NAFLD during the perimenopausal transition.

UK guidance supports case-finding for NAFLD in high-risk groups—particularly people with type 2 diabetes, obesity, or metabolic syndrome—irrespective of menopausal status. Menopausal status alone is not an indication for screening. Early identification allows for timely lifestyle interventions that can prevent disease progression.

How Hormonal Changes Affect Liver Health

The decline in oestrogen levels during perimenopause may have profound effects on metabolic processes that influence liver health. Oestrogen is thought to play a protective role in maintaining metabolic homeostasis, and its reduction can trigger several changes that may predispose to hepatic fat accumulation.

Oestrogen and lipid metabolism: Oestrogen is believed to help regulate lipid metabolism by influencing the production and clearance of lipoproteins. It may promote the breakdown of fatty acids and enhance insulin sensitivity in peripheral tissues. When oestrogen levels decline during perimenopause, there is often an increase in circulating triglycerides and low-density lipoprotein (LDL) cholesterol, whilst high-density lipoprotein (HDL) cholesterol may decrease. These lipid profile changes can contribute to fat deposition in the liver.

Insulin resistance: Oestrogen deficiency is associated with decreased insulin sensitivity, meaning cells may become less responsive to insulin's effects. This can lead to compensatory hyperinsulinaemia (elevated insulin levels), which promotes hepatic lipogenesis—the process by which the liver synthesises fatty acids from carbohydrates. Simultaneously, insulin resistance may impair the breakdown of fat in adipose tissue, leading to increased delivery of free fatty acids to the liver.

Body composition changes: During perimenopause, women typically experience a shift in fat distribution from peripheral (hips and thighs) to central (abdominal) locations. Visceral adipose tissue is metabolically active and releases inflammatory cytokines and free fatty acids directly into the portal circulation, which flows to the liver. This increased flux of fatty acids to the liver may promote steatosis.

Inflammatory processes: The hormonal transition may be associated with increased systemic inflammation, characterised by elevated levels of inflammatory markers such as C-reactive protein and interleukin-6. This pro-inflammatory state can contribute to the progression from simple steatosis to steatohepatitis, where liver inflammation and cellular damage occur.

Understanding these mechanisms highlights why perimenopausal women may benefit from targeted metabolic monitoring and preventive interventions to support liver health during this transitional period. However, individual variability is high, and not all women will experience these changes to the same degree.

Risk Factors for Fatty Liver During Perimenopause

Several risk factors can increase a woman's likelihood of developing fatty liver disease during the perimenopausal transition. Recognising these factors enables targeted case-finding and early intervention.

Metabolic risk factors:

• Obesity and increased BMI: Excess body weight, particularly with a BMI over 25 kg/m², significantly increases NAFLD risk. Central obesity is particularly concerning; waist circumference thresholds vary by ethnicity (for example, ≥80 cm for women of White European background; lower thresholds apply for women of South Asian, Chinese, and Japanese descent).

• Type 2 diabetes and insulin resistance: These conditions are strongly associated with NAFLD, with up to 70% of people with type 2 diabetes having some degree of fatty liver.

• Metabolic syndrome: The presence of three or more features—central obesity, elevated blood pressure, raised triglycerides, low HDL cholesterol, and elevated fasting glucose—substantially increases risk.

• Dyslipidaemia: Elevated triglycerides and LDL cholesterol, combined with low HDL cholesterol, contribute to hepatic fat accumulation.

Lifestyle factors:

• Sedentary behaviour: Physical inactivity reduces energy expenditure and promotes weight gain and insulin resistance.

• Dietary patterns: Diets high in refined carbohydrates, added sugars (particularly fructose), and saturated fats increase NAFLD risk. Excessive caloric intake relative to expenditure promotes fat storage.

• Alcohol consumption: NAFLD is defined in the context of low alcohol intake (≤14 units per week, in line with UK Chief Medical Officers' guidance). Even moderate consumption may exacerbate liver fat accumulation in susceptible individuals.

Medical and genetic factors:

• Polycystic ovary syndrome (PCOS): Women with PCOS have higher rates of insulin resistance and are at increased risk of NAFLD.

• Hypothyroidism: Underactive thyroid function can contribute to metabolic dysfunction and weight gain.

• Family history: Genetic predisposition plays a role, with certain gene variants (such as PNPLA3) increasing susceptibility.

• Medications: Some drugs may contribute to metabolic changes or steatosis, including corticosteroids, certain antipsychotics, tamoxifen, amiodarone, valproate, and methotrexate.

Early menopause: Women who experience menopause before age 45 may have prolonged exposure to oestrogen deficiency, potentially increasing their cumulative risk of metabolic complications including NAFLD.

Detection and risk stratification in the UK: If NAFLD is suspected (for example, in a woman with type 2 diabetes, obesity, or metabolic syndrome), your GP will:

• Assess liver function tests (LFTs) and metabolic risk factors

• Exclude other causes of abnormal LFTs (viral hepatitis, autoimmune liver disease, haemochromatosis, alcohol-related liver disease)

• Use non-invasive fibrosis tests to assess risk of advanced fibrosis. NICE recommends the Enhanced Liver Fibrosis (ELF) test for adults with confirmed NAFLD. In some areas, the FIB-4 score or NAFLD Fibrosis Score may be used in primary care.

• Reserve transient elastography (FibroScan) for intermediate- or high-risk results, or refer to specialist services for further assessment.

Women with multiple risk factors should discuss case-finding with their GP. Referral to a specialist is recommended if non-invasive fibrosis tests suggest advanced fibrosis, if LFTs remain abnormal for more than six months, or if there are signs of chronic liver disease.

Managing Liver Health Through the Menopause Transition

Effective management of liver health during perimenopause centres on lifestyle modifications that address the underlying metabolic changes. Evidence-based strategies can prevent NAFLD development or halt its progression in those already affected.

Weight management and dietary modifications: Achieving and maintaining a healthy weight is the cornerstone of NAFLD management. Even modest weight loss of 5–10% of body weight can significantly reduce liver fat and improve liver enzyme levels. NICE guidance emphasises structured weight loss programmes for individuals with NAFLD and obesity.

Dietary recommendations include:

• Following a Mediterranean-style diet rich in vegetables, fruits, whole grains, legumes, nuts, and olive oil

• Reducing intake of refined carbohydrates, added sugars, and sugar-sweetened beverages

• Limiting saturated fats and avoiding trans fats

• Choosing lean protein sources including fish, poultry, and plant-based proteins

• Moderating portion sizes to create a sustainable caloric deficit if weight loss is needed

• Keeping alcohol intake within UK low-risk guidelines (≤14 units per week, spread over three or more days)

Physical activity: Regular exercise improves insulin sensitivity, promotes weight loss, and may directly reduce liver fat independent of weight loss. In line with UK Chief Medical Officers' Physical Activity Guidelines, current recommendations suggest:

• At least 150 minutes of moderate-intensity aerobic activity weekly (such as brisk walking, cycling, or swimming)

• Resistance training twice weekly to maintain muscle mass, which declines during perimenopause

• Reducing sedentary time by incorporating movement throughout the day

Medical management: Whilst lifestyle modification remains first-line treatment, some women may benefit from additional interventions:

• Diabetes management: Optimising glycaemic control in women with type 2 diabetes is important. Certain diabetes medications (such as GLP-1 receptor agonists) may have incidental benefits on liver fat when used for their licensed indications (type 2 diabetes or obesity), though they are not licensed specifically for NAFLD or NASH in the UK.

• Lipid management: Statins may be appropriate for cardiovascular risk reduction (for example, using QRISK assessment) and are safe in NAFLD; they do not worsen liver disease in most cases.

• Specialist therapies: Pioglitazone may be considered for biopsy-proven NASH under specialist care, in line with NICE guidance. It should not be initiated in primary care for NAFLD.

• Hormone replacement therapy (HRT): Some evidence suggests HRT may have metabolic benefits during menopause. However, HRT should not be prescribed solely to treat or prevent NAFLD. Decisions should follow NICE guidance on menopause management and be individualised based on overall risk–benefit assessment. Transdermal routes may be preferred in women with hypertriglyceridaemia, and HRT should be avoided in active or severe liver disease.

Monitoring and follow-up: For adults with NAFLD and no advanced fibrosis, NICE recommends reassessing the risk of advanced fibrosis every three years using the ELF test (or local equivalent non-invasive fibrosis test). Review should be sooner if LFTs or symptoms change. Additional monitoring may include:

• Cardiovascular risk assessment, as NAFLD is associated with increased cardiovascular disease risk

• Screening for complications such as cirrhosis in advanced cases

Referral thresholds: Your GP should refer you to a specialist if:

• Non-invasive fibrosis tests (such as ELF or FIB-4) suggest advanced fibrosis

• LFTs remain persistently abnormal for more than six months

• There are signs of chronic liver disease (such as spider naevi, palmar erythema, or splenomegaly)

When to seek urgent medical advice: Seek same-day GP assessment or attend A&E if you experience:

• Jaundice (yellowing of skin or eyes) with systemic symptoms such as fever or confusion

• Signs of hepatic encephalopathy (confusion, drowsiness, altered behaviour)

• Gastrointestinal bleeding (vomiting blood or passing black, tarry stools)

When to contact your GP: Arrange a routine appointment if you experience:

• Unexplained persistent fatigue or malaise

• Abdominal discomfort, particularly in the right upper quadrant

• Unexplained weight loss

• Easy bruising or fluid retention

Proactive management during the perimenopausal transition can significantly reduce the risk of developing fatty liver disease and its potential complications. Women should discuss their individual risk factors with healthcare professionals to develop personalised prevention and management strategies that support long-term liver and metabolic health.

Frequently Asked Questions